rxstat › Classes › Other Antineoplastic Agents

Other Antineoplastic Agents: shortage status in Canada

5 of the 17 other antineoplastic agents rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Amsacrine (Amsa Pd) Partial shortage 1 of 1 reported products affected Arsenic Trioxide (Trisenox) Partial shortage 1 of 3 reported products affected Carboplatin Partial shortage 1 of 3 reported products affected Eribulin Partial shortage 1 of 1 reported products affected · est. return Aug 31, 2027 Erlotinib (Tarceva) Partial shortage 3 of 14 reported products affected · est. return Jun 30, 2027 Oxaliplatin (Eloxatin) Shortage anticipated 0 of 6 reported products affected Vemurafenib (Zelboraf) Shortage anticipated 0 of 1 reported products affected Aminolevulinic Acid (Levulan Kerastick) No current shortage Anagrelide (Agrylin) No current shortage Asparaginase (Kidrolase) Discontinued 0 of 2 reported products affected Estramustine (Emcyt) Discontinued 0 of 1 reported products affected Hydroxyurea (Hydrea) No current shortage Ipilimumab (Yervoy) No current shortage Methyl Aminolevulinate (Metvix) No current shortage Ofatumumab (Arzerra) Discontinued 0 of 2 reported products affected Olaparib (Lynparza) Discontinued 0 of 1 reported products affected Pembrolizumab (Keytruda) Discontinued 0 of 1 reported products affected

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.